Upcoming Global Web Symposia
Wednesday, March 23, 2011
11:30 a.m. - 1:00 p.m. EST
Course Description:Functional proteins (receptors, enzymes, ion channels) sense their world and adjust their reactivity to it through the process of allostery. This extremely important thermodynamic mechanism is becoming increasingly prevalent in drug discovery as the highthroughput screens for new drugs have changed from simple orthosterically oriented assays (such as binding) to highly sophisticated and information-rich functional assays, i.e. more and more allosteric hits are being observed. In response to this influx, discovery scientists need to be aware of how to detect, describe and otherwise think about allosteric ligands. This first module discusses the history of allostery, the present model used to describe it (modulator / conduit / guest) and the unique properties of allosteric molecules.
Learning Objectives:This session is designed to solve a problem, namely the use of thermodynamic principles and practical pharmacology to detect allostery as a mechanism of action in drug candidate molecules.
Students will learn why allosterism is a unique and therapeutically useful mechanism of action for drugs with special reference to the properties of allosteric molecules. We will also consider what makes allosteric modulators different from conventional molecules that interact with the natural protein binding site; these data are directly relevant to making choices of chemical targets for new drug discovery programs.
Instructor Information: Terry Kenakin Ph.D.
Professor, Department of Pharmacology
University of North Carolina School of Medicine
Chapel Hill NC
Instructor Biography:Terrence Kenakin, Ph.D., is Professor in the Department of Pharmacology, University of North Carolina, Chapel Hill. Until August of 2011, Dr. Kenakin was director of research at GlaxoSmithKline Research and Development laboratories at Research Triangle Park, NC where he optimized drug activity assay systems for the discovery and testing of. allosteric molecules mostly for the treatment of diabetes. Before starting the major stint of his drug discovery career at GSK, Dr. Kenakin was an associate scientist at Burroughs-Wellcome in the U.K. which he joined after a post-doctoral fellowship at University College London, U.K. Dr. Kenakin earned his Ph.D. in Pharmacology at the University of Alberta, Edmonton Canada.
Dr. Kenakin is a member of many editorial boards as well as Co-editor-in-Chief of the Journal of Receptors and Signal Transduction. In addition, he has authored numerous articles and has written eight books on pharmacology, including the popular "A Pharmacology Primer".
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: firstname.lastname@example.org
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesreportsbarnett educational servicesconsultingpublications & eNewslettersprofessional services
executive teamtestimonialschi timelinemailing listcareers